Exclusive outtakes from industry leaders
AUDIO-Glaxo sees 50/50 split with Merck in cancer vaccine market
GlaxoSmithKline may trail Merck & Co in bringing to market a vaccine for cervical cancer, but Glaxo CEO JP Garnier says its Cervarix will eventually split the market with Merck’s Gardasil.
Cervarix is already available in Europe, but is still pending approval in the United States, where Gardasil is well established. It may take a few years, but Garnier tells the Reuters Health Summit in a phone interview this week that Glaxo will build the brand and catch-up.